1Wk·

Genmab Q3 2024 $GMAB (-3.33%)

attachment




Financial performance:

  • Revenue: Total revenue for the first nine months of 2024 amounted to DKK 15.085 million, an increase of 29% compared to DKK 11.715 million in the same period in 2023.
  • Net profit: Net profit for the first nine months of 2024 amounted to DKK 3.999 million, compared to DKK 3.649 million in the same period last year.


Balance sheet overview:

  • Total assets: As of September 30, 2024, total assets amounted to DKK 39.660 million, an increase against DKK 35.335 million as of December 31, 2023.
  • Equity: Equity at September 30, 2024 was DKK 31.922 million, compared to DKK 31.656 million at December 31, 2023.


Profit and loss account:

  • Operating result: Operating profit for the first nine months of 2024 amounted to DKK 4,543 million, compared with DKK 3,570 million in the prior-year period.
  • Operating expenses: Operating expenses amounted to DKK 10.542 million compared to DKK 8.145 million in the same period in 2023.


Cash flow overview:

  • Operating activities: Net cash flow from operating activities amounted to DKK 5,059 million for the first nine months of 2024, compared with DKK 5,708 million in the same period in 2023.
  • Investing activities: Net cash flow for investing activities amounted to DKK -9.989 million, primarily due to the acquisition of ProfoundBio.
  • Financing activities: Net cash flow for financing activities amounted to DKK -3.922 million, primarily due to the repurchase of own shares.


Key ratios and profitability metrics:

  • Equity ratio: Equity ratio decreased to 80% at September 30, 2024, compared to 90% at December 31, 2023.
  • Earnings per share: Basic earnings per share for the first nine months of 2024 amounted to DKK 62.09, compared with DKK 55.88 in the prior-year period.


Competitive position:

  • Genmab has entered into over 20 strategic partnerships with companies in the biotechnology and pharmaceutical industries.


Forecasts and management commentary:

  • Revenue forecast: Revenue guidance for 2024 updated to DKK 21.1 - 21.7 billion, reflecting growth of 30% YoY.
  • Operating profit: Operating profit forecast raised to DKK 6.2 - 7.1 billion (excluding acquisition and integration costs).


Risks and opportunities:

  • Risks: A lawsuit filed by Chugai in Japan against Genmab and AbbVie for alleged patent infringement in connection with EPKINLY.
  • Opportunities: Expansion of the product pipeline and further development of own clinical products.


Summary of results:


Positive aspects:

  • Sales growth: Sales increase of 29%.
  • Net profit increase: Net profit increased to DKK 3,999 million.
  • Strategic acquisitions: Acquisition of ProfoundBio to strengthen the product pipeline.
  • Improved forecast: Adjusted revenue and operating profit forecast.
  • Strong partnerships: More than 20 strategic partnerships.


Negative aspects:

  • Decrease in cash flow: Decrease in cash generated from operating activities.
  • Rising liabilities: Increased level of debt.
  • Decrease in equity ratio: Decrease in equity ratio from 90% to 80%.
  • Patent lawsuit: Ongoing patent lawsuit in Japan.
  • High acquisition costs: High capital outflow due to the acquisition of ProfoundBio.
2
2 Comments

profile image
It actually looks very good. Surprising that the share has reacted zero😂
1
Show answer
Join the conversation